With our increasing understanding of the extensive molecular heterogeneity of cancers, and the current trajectory of the field towards the prosecution of precision medicine, one of the important considerations regarding the exploitation of anti-CXCL8-CXCR1/2 therapeutics will be establishing which tumors are susceptible to such inhibitors. Here, CXCR1 is linked to cancer.